Literature DB >> 9038270

Molecular characterization of adenocarcinoma of the cervix.

M F Parker1, G F Arroyo, J Geradts, A L Sabichi, R C Park, R R Taylor, M J Birrer.   

Abstract

In an attempt to characterize the molecular alterations of cervical adenocarcinoma, we analyzed 32 paraffin-embedded specimens for the presence of K-ras mutations, p53 overexpression, p16 and Rb protein expression, and the presence of HPV 16 and 18 DNA. Overall 25/32 (78%) of the tumors displayed an abnormality in at least one of these analyses. K-ras mutations were detected by PCR amplification and RFLP analysis in 3 tumors, including 2 at codon 12 and 1 at codon 61. p53 overexpression determined by immunohistochemistry was demonstrated with > 80% of tumor nuclei staining in 4 cases, 10-15% of nuclei staining in 3 cases, and < 1% of nuclei staining in 5 cases. The pattern of staining was diffuse in 6 cases, focal in 1 case, and scattered in 5 cases. Analysis of p16 protein expression in 23 specimens revealed 1 tumor with abnormal staining, while Rb protein expression was determined to be normal in all 25 tumors tested. HPV DNA, detected by PCR with type-specific primers, was found in 16 tumors (50%), including 7 (22%) with HPV 16 and 9 (28%) with HPV 18. There was no correlation among these abnormalities except that the presence of HPV and strong p53 overexpression (> 80% tumor nuclei staining) were mutually exclusive events. Clinical correlation demonstrated that p53 overexpression involving the majority of tumor cell nuclei is characteristic of advanced stage disease, while HPV positivity and activated ras genes are associated with early stage disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038270     DOI: 10.1006/gyno.1996.4580

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma.

Authors:  E C Pirog; B Kleter; S Olgac; P Bobkiewicz; J Lindeman; W G Quint; R M Richart; C Isacson
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype.

Authors:  Yasuki Kusanagi; Atsumi Kojima; Yoshiki Mikami; Takako Kiyokawa; Tamotsu Sudo; Satoshi Yamaguchi; Ryuichiro Nishimura
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

3.  Oncosuppressor proteins of fragile sites are reduced in cervical cancer.

Authors:  Enrico Giarnieri; Nicola Zanesi; Arianna Bottoni; Mauro Alderisio; Ankica Lukic; Aldo Vecchione; Vincenzo Ziparo; Carlo Maria Croce; Rita Mancini
Journal:  Cancer Lett       Date:  2009-08-22       Impact factor: 8.679

Review 4.  Molecular events in uterine cervical cancer.

Authors:  S A Southern; C S Herrington
Journal:  Sex Transm Infect       Date:  1998-04       Impact factor: 3.519

5.  Changes in retinoblastoma gene expression during cervical cancer progression.

Authors:  Mauricio Salcedo; Lucía Taja; Dolores Utrera; Pedro Chávez; Alfredo Hidalgo; Carlos Pérez; Luis Benítez; Cristina Castañeda; Ricardo Delgado; Patricio Gariglio
Journal:  Int J Exp Pathol       Date:  2002-12       Impact factor: 1.925

6.  Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma.

Authors:  Tomomi Yoshida; Takaaki Sano; Tetsunari Oyama; Tatsuya Kanuma; Toshio Fukuda
Journal:  Virchows Arch       Date:  2009-09       Impact factor: 4.064

7.  Alteration of p16 and p15 genes in human uterine tumours.

Authors:  R Nakashima; M Fujita; T Enomoto; T Haba; K Yoshino; H Wada; H Kurachi; M Sasaki; K Wakasa; M Inoue; G Buzard; Y Murata
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.